Sentence examples for vaccines under study from inspiring English sources

Now Peter Piot, who discovered Ebola in 1976, David Heymann, the director of the Chatham House Centre on Global Health Security and Jeremy Farrar from the Wellcome Trust have said there are in fact several drugs and vaccines under study that could be used to combat the disease.

The vaccines under study are designed for use in East Africa, primarily, and are based on Clade A HIV-1, which is prevalent there.

In model 1, the disproportionality information summarized by the PRR estimate and its 95%% lower limit poorly predicted the presence of AEs in the GPI for the eight vaccines under study.

Indirectly, it would also assess if it is as good a predictor for drug emerging safety signals as it was for events listed in the GPI of the GSK vaccines under study.

The original dataset contained 9474 V Es to be modelled for their probability of being an ARFI, using the three logistic regression models based on data from the eight vaccines under study; 803 (8.5 %) were considered as ARFIs based on the safety information from the GPI.

Taking the GPI as a proxy of the list of events causally associated with the vaccines, we can conclude that temporality seems to be a stronger predictor of causality than the strength of association for the eight vaccines under study, at least when temporality and strength of association are estimated in the context of spontaneous report data.

A variety of vaccine platforms are under study for development of new vaccines for measles.

The efficacy of the vaccine is still under study, therefore, we refer to previous estimates and perform a sensitivity analysis to explore higher and lower efficacy levels.

Matching persons identified with cases of the vaccine-preventable disease under study to their registry immunization records is likely to be a first step in many registry-based vaccine effectiveness studies.

Second, the ease of collecting immunization data from a registry also means that cohort studies could be conducted even in populations with low incidence of the vaccine-preventable disease under study.

By the year 2010, I believe, several of the most promising H.I.V. vaccine candidates could be under study in controlled clinical trials in countries with the highest rates of new H.I.V. infection.